Arcus Biosciences Stock Investor Sentiment

RCUS Stock  USD 16.44  0.50  3.14%   
Slightly above 54% of Arcus Biosciences' investor base is interested to short. The analysis of the overall investor sentiment regarding Arcus Biosciences suggests that many traders are impartial. Arcus Biosciences' investing sentiment can be driven by a variety of factors including economic data, Arcus Biosciences' earnings reports, geopolitical events, and overall market trends.
  

Arcus Biosciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Arcus Biosciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at businesswire.com         
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
businesswire News
over six months ago at zacks.com         
Arcus Biosciences, Inc. Reports Q1 Loss, Tops Revenue Estimates
zacks News
over six months ago at news.google.com         
Arcus Biosciences Scheduled to Post Quarterly Earnings on Wednesday - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Zurcher Kantonalbank Zurich Cantonalbank Has 361000 Stock Position in Arcus Biosciences, Inc. - Defe...
Google News at Macroaxis
over six months ago at news.google.com         
RCUS Owner Earnings per Share - GuruFocus.com
Google News at Macroaxis
over six months ago at news.google.com         
Handelsbanken Fonder AB Invests 244000 in Arcus Biosciences, Inc. - Defense World
Google News at Macroaxis
over six months ago at businesswire.com         
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
businesswire News
over six months ago at zacks.com         
Will Arcus Biosciences, Inc. Report Negative Earnings Next Week What You Should Know
zacks News
over six months ago at news.google.com         
Short Interest in Arcus Biosciences, Inc. Declines By 17.1 percent - MarketBeat
Google News at Macroaxis
over six months ago at businesswire.com         
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeli...
businesswire News
over six months ago at www.macroaxis.com         
Disposition of 34070 shares by Jennifer Jarrett of Arcus Biosciences at 20.11 subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
Assenagon Asset Management S.A. Purchases Shares of 47253 Arcus Biosciences, Inc. - Defense World
Google News at Macroaxis
over six months ago at news.google.com         
Arcus Biosciences, Inc. Shares Purchased by Vanguard Group Inc. - Defense World
Google News at Macroaxis
over six months ago at finance.yahoo.com         
Investors bid Arcus Biosciences up US219m despite increasing losses YoY, taking five-year CAGR to 8....
Yahoo News
over six months ago at news.google.com         
Arcus Biosciences, Inc. COO Sells 202720.05 in Stock - Defense World
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Arcus Biosciences that are available to investors today. That information is available publicly through Arcus media outlets and privately through word of mouth or via Arcus internal channels. However, regardless of the origin, that massive amount of Arcus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Arcus Biosciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Arcus Biosciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Arcus Biosciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Arcus Biosciences alpha.

Arcus Biosciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Arcus Biosciences growing losses dont faze investors as the stock jumps 13 percent this past week
10/09/2024
2
First Clinical Data for Arcus Biosciences HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidne...
10/24/2024
3
Arcus Biosciences Advancing On Several Fronts - Seeking Alpha
10/29/2024
4
This Arcus Biosciences Insider Reduced Their Stake By 27
10/31/2024
5
What To Expect From Arcus Biosciences Inc Q3 2024 Earnings
11/05/2024
6
Arcus Biosciences Inc Q3 2024 Earnings Call Highlights Strong Cash Position and ...
11/07/2024
7
Arcus Biosciences, Inc. Q3 2024 Earnings Call Transcript
11/08/2024
8
FMR LLC Bolsters Stake in Arcus Biosciences Inc
11/13/2024
9
Arcus Biosciences, Inc.s Price Is Right But Growth Is Lacking
11/21/2024

Additional Tools for Arcus Stock Analysis

When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.